SCHEMBL1997677

SCHEMBL1997677

C=CCN1C(=O)CN(Cc2ccc(-c3cccc(CN4CCC(F)(F)CC4)c3)cc2)C1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 2/20 0.39
CNR1 P21554 3/20 0.37
CNR2 P34972 3/20 0.37
HRH3 Q9Y5N1 1/20 0.35
JAK2 O60674 1/20 0.35
JAK1 P23458 1/20 0.35
TYK2 P29597 1/20 0.35
JAK3 P52333 1/20 0.35
DRD2 P14416 3/20 0.35
HDAC6 Q9UBN7 1/20 0.35
DRD4 P21917 1/20 0.35
DRD3 P35462 1/20 0.35
MCHR1 Q99705 3/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C19 P33261 1/20 0.35
NR1H2 P55055 1/20 0.35
BACE1 P56817 1/20 0.35
LSS P48449 1/20 0.34
HTR1A P08908 1/20 0.34
SIGMAR1 Q99720 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1998338 0.83 MCHR1 (0.40) ENPP2CNR1CNR2HRH3JAK2
SCHEMBL1996322 0.80 CNR1 (0.44) CNR1CNR2HRH3JAK2JAK1
SCHEMBL1997569 0.75 CYP2D6 (0.49) ENPP2HRH3DRD2HDAC6DRD4
SCHEMBL1998795 0.75 CYP2D6 (0.49) ENPP2HRH3HDAC6MCHR1CYP2D6
SCHEMBL2002675 0.72 DHODH (0.43) ENPP2HRH3JAK1DRD2HDAC6
SCHEMBL1998174 0.72 CYP2D6 (0.48) ENPP2HRH3MCHR1CYP2D6CYP2C19
SCHEMBL1998115 0.70 LMNA (0.41) ENPP2HRH3JAK2JAK1TYK2
SCHEMBL1998347 0.69 METAP2 (0.41) ENPP2HRH3HDAC6BACE1
SCHEMBL1997408 0.69 ENPP2 (0.49) ENPP2HRH3DRD2DRD4CYP2D6
SCHEMBL1999482 0.68 ENPP2 (0.48) ENPP2HRH3JAK2JAK1TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960560-B2 1-(biphenyl-4-ylmethyl)imidazolidine-2,4-dione N.V. ORGANON (NL) 2011-06-14 US claimed
US-20100144723-A1 1-(BIPHENYL-4-YLMETHYL)IMIDAZOLIDINE-2,4-DIONE N. V. ORGANON 2010-06-10 US claimed
EP-2373627-A1 1- (BIPHENYL-4-YLMETHYL) IMIDAZOLIDINE-2, 4-DIONE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS N.V. Organon (NL) 2011-10-12 EP disclosed
US-7960560-B2 1-(biphenyl-4-ylmethyl)imidazolidine-2,4-dione N.V. ORGANON (NL) 2011-06-14 US disclosed
US-20100144723-A1 1-(BIPHENYL-4-YLMETHYL)IMIDAZOLIDINE-2,4-DIONE N. V. ORGANON 2010-06-10 US disclosed
WO-2010063721-A1 1- (BIPHENYL-4-YLMETHYL) IMIDAZOLIDINE-2, 4-DIONE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS N.V. ORGANON (NL) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144723-A1 1-(BIPHENYL-4-YLMETHYL)IMIDAZOLIDINE-2,4-DIONE OPRM1, OR10J3, OPRD1 ENPP2 1556/4885CNR1 6/4885CNR2 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.